US Coalition for Vaccine Safety takes another swipe at regulators, this time over Merck & Co's Gardasil
The USA's Coalition for Vaccine Safety claims that a three-part investigative series on US drug giant Merck & Co's cervical cancer vaccine, Gardasil highlights serious conflicts of interest across agencies of the Department of Health and Human Services (DHHS) in the development, approval and safety surveillance of vaccines.
The series, by Mark Blaxill, editor-at-large for the Internet newspaper Age of Autism and a director of SafeMinds, was posted on the newspaper's site on May 12-13. This was preceded the announcement that a Food and Drug Administration advisory panel recommended allowing use of rotavirus vaccines despite their contamination with viral particles from pigs, following which the CVS called for the immediate withdrawal of such products, saying it was 'shocked' at such advice (The Pharma Letter May 11).
'Unprecedented public-private partnership' with drugmakers
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze